Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FSH Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

NCT01340521
View directory record Official record
Conditions
Infertility
Interventions
Clomiphene Citrate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 1994
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Jul 22, 2026, 5:41 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Letrozole Treatment in Normal and GnRH Deficient Women

NCT00351416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Letrozole, NAL-GLU GnRH antagonist
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jul 22, 2026, 5:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions
AOC-1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Orange, California • Palo Alto, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

NCT01044862
View directory record Official record
Conditions
Pregnancy, Unexplained Infertility
Interventions
Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

NCT03740737
View directory record Official record
Conditions
Infertility
Interventions
Follitropin delta, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Jul 22, 2026, 5:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

NCT00082108
View directory record Official record
Conditions
Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2, Congenital Myotonic Dystrophy, PROMM (Proximal Myotonic Myopathy), Steinert's Disease, Myotonic Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 4 Interventional

Luteal Phase FSH in the IVF Poor Responder

NCT00225433
View directory record Official record
Conditions
Infertility
Interventions
follitropin beta, ganirelix acetate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 42 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 22, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional

A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

NCT05403476
View directory record Official record
Conditions
Male Idiopathic Infertility
Interventions
FE 999049, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Tempe, Arizona • San Jose, California • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 3 Interventional

Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF

NCT00378001
View directory record Official record
Conditions
Infertility
Interventions
FSH-IBSA, GONAL-F
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

NCT00614406
View directory record Official record
Conditions
Ovulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days), Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Interventions
Celebrex, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 5:41 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

TMS-Induced LH Response in Healthy Women in Luteal Phase

NCT07363421
View directory record Official record
Conditions
Healthy Women
Interventions
Transcranial Magnetic Stimulation Active, Transcranial Magnetic Stimulation Sham
Device
Lead sponsor
The City College of New York
Other
Eligibility
22 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NCT02478775
View directory record Official record
Conditions
Obesity, Fertility
Interventions
Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 22, 2026, 5:41 AM EDT
Terminated Early Phase 1 Interventional

The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve

NCT01129830
View directory record Official record
Conditions
Infertility
Interventions
dehydroepiandrosterone
Dietary Supplement
Lead sponsor
Virginia Center for Reproductive Medicine
Other
Eligibility
21 Years to 44 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808
View directory record Official record
Conditions
Egg Donation
Interventions
Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes
Drug · Procedure
Lead sponsor
Michigan Reproductive Medicine
Other
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 22, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

NCT06414096
View directory record Official record
Conditions
Infertility, Obesity
Interventions
Follicle Stimulating Hormone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 37 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 5:41 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause

NCT03856268
View directory record Official record
Conditions
Menopause Surgical, Estrogen Deficiency, Adiposity, Follicle-Stimulating Hormone Deficiency, Hormone Deficiency
Interventions
'Surgical Menopause' Group, 'Drug-Induced Menopause' Group
Procedure · Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

NCT03203681
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Natesto
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles

NCT01286051
View directory record Official record
Conditions
Compare Pregnancy Rates Between FSH Stimulation and FSH and, GnRH Antagonist
Interventions
Follistim administration, Follistim plus Ganirelix
Drug
Lead sponsor
Houston Fertility Institute
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

NCT02310919
View directory record Official record
Conditions
Infertility
Interventions
Low dose hCG plus FSH co-trigger, Standard dose of hCG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)

NCT01223079
View directory record Official record
Conditions
Outcome During r-hFSH Stimulation, Outcome During r-hFSH and r-hLH Stimulation
Interventions
r-hFSH, r-hFSH and r-hLH
Drug
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
21 Years to 32 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Jul 22, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

NCT00064987
View directory record Official record
Conditions
Hypogonadism, Kallmann Syndrome
Interventions
Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH)
Procedure · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

NCT00027391
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
Albuterol, Oxandrolone
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 22, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population

NCT02554279
View directory record Official record
Conditions
Infertility
Interventions
menotropin, recombinant FSH
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
21 Years to 35 Years · Female only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 5:41 AM EDT